Pharm-Olam is now Allucent. Learn More
In the past several years, Pharm-Olam has completed 75+ Infectious Disease studies and served 19,600+ patients across 1,600+ sites. To put those numbers in perspective, 85% of PMs and 80% of CRAs currently on staff have worked in infectious disease research.
Pharm-Olam's teams have deep expertise in supporting studies in an ICU/critical care setting and navigating the common challenges encountered in this complex environment. That knowledge enables us to provide proactive and insightful CRO services for indications from Pneumonia to COVID-19 and everywhere in between.
Pharm-Olam has collaborated with multiple government agencies, including CDC, DOD, and NIH. Pharm-Olam is also a member of the Medical CBRN Defense Consortium (MCDC) and was selected by BARDA to support Medical Countermeasure (MCM) development for the next two years.
Pharm-Olam supports clinical trials in over 60+ countries. We help our Sponsors rapidly deploy their studies and maximize the subject recruitment period to deliver on-time and on-budget through our global reach and local insights.